AzTrials
AzTrials

Anatomic Stage IIB Breast Cancer AJCC v8Phase 2NCT03872388

Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy

A Phase 2 study testing Atorvastatin and Capecitabine in people with Anatomic Stage IIB Breast Cancer AJCC v8 and Anatomic Stage III Breast Cancer AJCC v8, run by M.D. Anderson Cancer Center at 5 sites in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record

Search all trials

Trial summary

This phase II trial studies how well atorvastatin works in treating patients with stages IIb-III triple negative breast cancer who did not achieve a pathologic complete response to neoadjuvant chemotherapy. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Atorvastatin and Capecitabine
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
6 participants
Where
5 sitesUnited States
Study dates
23 Sep 2019to 19 Oct 2023
Phase
Phase 2

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Is willing and able to provide written informed consent for the trial
  • Diagnosis of TNBC (including patients with a clinical diagnosis of triple negative inflammatory breast cancer)
  • Has histological confirmation of breast carcinoma
  • Have stage IIB or III disease as defined by the American Joint Committee on Cancer version 7 or 8
  • Has confirmed TNBC, defined as having estrogen and progesterone receptor < 10% positivity by immunohistochemistry (IHC) and HER2 normal, which is 0 or 1+ by IHC and negative by fluorescence in situ hybridization (FISH) if performed or HER2 2+ by IHC and negative by FISH or HER2 negative by FISH if IHC is not performed
  • Received neoadjuvant chemotherapy and did not achieve pCR nor had an RCB-I (we will enroll patients with an RCB-II or RCB-III) following neoadjuvant chemotherapy. Since the RCB index has not been validated in IBC, any amount of residual disease will be allowed. pCR is defined as: a) the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy (i.e., ypT0/Tis ypN0 in the current American Joint Committee on Cancer [AJCC] staging system). Or b) the absence of residual invasive and in situ cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy (i.e., ypT0 ypN0 in the current AJCC staging system)
Show all 16Show fewer
  • Has a performance status of 0-1 on the Eastern Cooperative Oncology Group (ECOG) performance scale
  • Absolute neutrophil count (ANC) >= 1,500/mcL
  • Platelets >=100,000 /mcL
  • Hemoglobin (Hgb) >= 8 g/dL
  • Creatinine levels < 2.0 x upper limit of normal (ULN)
  • Total bilirubin =< 1.5 x ULN
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN
  • Subjects of childbearing potential should be willing to use effective methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through at least 4 months after the last dose of study drug; subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year; effective methods of birth control include 1). Use of hormonal birth control methods: pills, shots/injections, implants (placed under the skin by a health care provider), or patches (placed on the skin); 2). Intrauterine devices (IUDs); 3). Using 2 barrier methods (each partner must use 1 barrier method) with a spermicide. Males must use the male condom (latex or other synthetic material) with spermicide. Females must choose either a diaphragm with spermicide, or cervical cap with spermicide, or a sponge (spermicide is already in the contraceptive sponge)
  • Within 3 months from completion of definitive surgery after neoadjuvant chemotherapy
  • Willing to take statin for minimum of two years

Who cannot join

  • Has not recovered from adverse events due to prior therapies, i.e. monoclonal antibody, chemotherapy, targeted small molecule therapy, radiation therapy, or surgery
  • Note: Subjects with =< grade 2 neuropathy, alopecia and general disorders and administration site conditions are an exception to this criterion and may qualify for the study
  • Has a known malignancy (other than breast cancer) except basal cell carcinoma or squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy
  • Has known psychiatric or substance abuse disorders and assessed by attending physician that would interfere with cooperation with the requirements of the trial
  • Has received prior therapy with a statin within past 6 months or is currently receiving statin therapy; patients who previously received a statin more than 6 months prior to beginning study therapy and who discontinued treatment for reasons other than severe toxicity or allergic reaction are eligible
  • Is currently receiving another anti-lipidemic agent other than statin: fibric acid derivatives (i.e. fenofibrate, gemfibrozil), bile acid sequestrants (i.e. cholestyramine, colestipol), ezetimibe, niacin, lovaza (omega-3-acid ethyl esters), red yeast rice, orlistat, phytosterol, and lomitapide
Show all 12Show fewer
  • Known hypersensitivity to statin or any component of the formulation
  • Active liver disease or unexplained persistent elevations of serum transaminases, defined as elevated transaminases > 3 x ULN on at least 2 separate occasions 1 week apart
  • Pregnancy or women who may become pregnant and not on acceptable form of contraception; lactating women
  • Has evidence of distant metastasis
  • Record of myocardial infarction within 6 months before starting therapy, symptomatic congestive heart failure (New York Heart Association > class II), unstable angina, or unstable cardiac arrhythmia requiring medication
  • Chronic steroid use as this may prevent any immunomodulatory roles of statin treatment, defined as anticipating need of supraphysiologic dose of steroids for at least 12 weeks while on study

Trial locations and contacts

5 sites in 1 country.

5 sites in 1 country

United States5 sites

  • Piedmont Healthcare

    Atlanta, Georgia, 30309

  • Cooper Hospital University Medical Center

    Camden, New Jersey, 08103

  • Banner - MD Anderson Cancer Center

    Gilbert, Arizona, 85234

  • Banner - MD Anderson Cancer Center -Northern Colorado

    Greeley, Colorado, 80631

  • M D Anderson Cancer Center

    Houston, Texas, 77030

Other trials in United States

About this study

Official title: Atorvastatin in Triple-Negative Breast Cancer (TNBC) Patients Who Did Not Achieve a Pathologic Complete Response (pCR) After Receiving Neoadjuvant Chemotherapy, a Multicenter Pilot Study

This phase II trial studies how well atorvastatin works in treating patients with stages IIb-III triple negative breast cancer who did not achieve a pathologic complete response to neoadjuvant chemotherapy. Pathologic complete response is the lack of all signs of cancer in tissue samples removed during surgery after upfront chemotherapy. Atorvastatin is used for the treatment of high cholesterol and may reduce the risk of triple negative breast cancer from coming back. Triple-negative breast cancer is a type of breast malignancy that is comprised of cancer cells that do not have estrogen receptors, progesterone receptors, or large amounts of HER2/neu protein. Patients with TNBC do not have established systemic therapies such as anti-estrogens or HER2-targeting agents to reduce recurrence after surgery, and residual cancer found at surgery is associated with higher relapse rate.

Read the detailed description

PRIMARY OBJECTIVES:

  1. To determine the proportion of patients with undetectable circulating tumor cells (CTCs) at 6 months in patients with stage IIB/III triple negative breast cancer (TNBC) who did not achieve a pathologic complete response a (pCR) or Residual Cancer Burden-I (RCB-I) after receiving neoadjuvant chemotherapy (NAC) with and without atorvastatin therapy.

SECONDARY OBJECTIVES:

  1. To determine if baseline fasting lipid profile level (low density lipoprotein cholesterol [LDL-C]) and/or change in serum lipid levels are a predictive biomarker of change in the proportion of patients with CTCs.

II. To assess effect of biomarkers on atorvastatin treatment response, defined as CTCs, circulating tumor deoxyribonucleic acid (DNA) (ctDNA), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), serum Interleukin-6 (IL-6) and other inflammatory cytokines, for the purpose of identifying the optimal patient population for future larger scale adjuvant studies.

III. To determine if baseline fasting lipid profile level (LDL-C) and/or change in serum lipid levels are associated with 2-year relapse free survival (RFS) rate.

IV. To determine if baseline CRP and/or change in serum lipid levels are a predictive biomarker of change in the proportion of patients with CTCs.

  1. To determine if baseline C-reactive protein (CRP) and/or change in CRP are associated with 2-year RFS rate.

VI. To determine if baseline absolute number of CTCs and/or CTC change are associated with 2-year RFS rate.

VII. To estimate the 2-year RFS rate of patients with TNBC who did not achieve pCR with and without atorvastatin therapy.

VIII. To describe the toxicity and adverse events profile of atorvastatin treatment when given concurrently with standard doses of radiotherapy to the chest wall and regional nodes.

EXPLORATORY OBJECTIVES:

  1. To evaluate the correlation between multiplexed imaging biomarkers in the normal or tumor tissue taken at the time of surgery, and response to atorvastatin-induced CTC changes or with measured outcomes.

OUTLINE: Patients are assigned to 1 of 2 groups.

GROUP I: Patients receive standard of care atorvastatin orally (PO) once daily (QD) for up to 24 months. A physical exam is performed, and blood drawn at 3, 6, 12, 18 and 24 months after starting standard of care treatment or at any time the disease appears to get worse.

GROUP II: Patients not eligible to receive atorvastatin, will be enrolled into non-statin observation group with/without capecitabine treatment.

Medical subject headings
Inflammatory Breast Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AtorvastatinDrug

    Patients will receive Atorvastatin per ASCVD guidelines dosed as either a moderate intensity (20mg/day) or high intensity statin (80mg/day). Tablets are available in either 20mg or 80mg and will be dispensed as per standard of care for up to 24 months as part of the study.

    Patients may also receive capecitabine concurrently with Atorvastatin per physician discretion as standard of care. Standard of care dosing of Capecitabine is a 21 day cycle consisting 14 days on and 7 days off. The starting dosing will be per physician discretion, but may be up to 2500mg/m2 per day.

  • CapecitabineDrug

    Also called Ro 09-1978/000, Xeloda

    Patients not eligible to receive atorvastatin in group II will be enrolled into non-statin observation group with/without capecitabine treatment. Capecitabine administration will be dosed as per standard of care. Standard of care dosing of Capecitabine is a 21 day cycle consisting 14 days on and 7 days off. The starting dosing will be per physician discretion, but may be up to 2500mg/m2 per day.

Study groups in NCT03872388
Study groupRoleWhat they receive
Group I (atorvastatin)ExperimentalPatients receive standard of care atorvastatin PO QD for up to 24 months.
Receives: Drug: Atorvastatin
Group II (capecitabine)Active comparatorPatients not eligible to receive atorvastatin, will be enrolled into non-statin observation group with/without capecitabine treatment.
Receives: Drug: Capecitabine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Proportions of Patients With Undetectable Circulating Tumor Cells (CTC)

    Estimate the proportion of patients with undetectable circulating tumor cells (CTCs) at 6 months in patients with stage IIB/III TNBC who did not achieve a pCR or Residual Cancer Burden-I (RCB-I) after receiving neoadjuvant chemotherapy (NAC) with and without atorvastatin therapy.

    Measured: At 6 months

Secondary outcomes (8)

  1. Fasting Lipid Profile Level (Low Density Lipoprotein Cholesterol [LDL-C]) and/or Change in Serum Lipid Levels

    Determine if baseline fasting lipid profile level (LDL-C) and/or change in serum lipid levels are a predictive biomarker of change in the proportion of patients with CTCs.

    Measured: Baseline up to 2 years

  2. Biomarkers on Atorvastatin Treatment Response

    Assess effect of biomarkers on atorvastatin treatment response, defined as CTCs, circulating tumor DNA (ctDNA), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), serum Interleukin-6 (IL-6) and other inflammatory cytokines, for the purpose of identifying the optimal patient population for future larger scale adjuvant studies.

    Measured: Up to 2 years

  3. Fasting Lipid Profile Level (LDL-C) and 2-year RFS Rate

    Fasting lipid profile level (LDL-C) and 2-year RFS rate

    Measured: Baseline up to 2 years

  4. Baseline C-reactive Protein (CRP) and/or Change in Serum Lipid Levels

    Determine if baseline CRP and/or change in serum lipid levels are a predictive biomarker of change in the proportion of patients with CTCs.

    Measured: Baseline up to 2 years

  5. CTCs and 2-year RFS Rate

    Determine if baseline absolute number of CTCs and/or CTC change are associated with 2-year RFS rate.

    Measured: Baseline up to 2 years

  6. Recurrence-free Survival (RFS)

    Estimate the 2-year RFS rate of patients with TNBC who did not achieve pCR with and without atorvastatin therapy.

    Measured: At 2 years

  7. Incidence of Adverse Events

    Adverse events, grade and relationship will be tabulated by treatment arms.

    Measured: Up to 24 months

  8. C-reactive Protein (CRP) and 2-year RFS Rate

    Determine if baseline C-reactive protein (CRP) and/or change in CRP are associated with 2-year RFS rate.

    Measured: Baseline up to 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Mar 2019
  2. Study start23 Sep 2019
  3. Primary completion19 Oct 2023
  4. Study completion19 Oct 2023

Why it stopped: Due to slow accrual

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
6 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03872388
Sponsor's protocol ID
2018-0550
Other IDs
NCI-2019-00004, 2018-0550
Status last verified
Sep 2024
First submitted
11 Mar 2019
Last updated
2 Oct 2024
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in